KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Preferred Shares (2016 - 2018)

Teva Pharmaceutical Industries filings provide 4 years of Preferred Shares readings, the most recent being $3.8 billion for Q3 2018.

  • On a quarterly basis, Preferred Shares rose 5.66% to $3.8 billion in Q3 2018 year-over-year; TTM through Sep 2018 was $3.8 billion, a 5.66% increase, with the full-year FY2017 number at $3.6 billion, changed 0.3% from a year prior.
  • Preferred Shares hit $3.8 billion in Q3 2018 for Teva Pharmaceutical Industries, up from $3.8 billion in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $3.8 billion in Q3 2018 to a low of $3.3 billion in Q4 2015.
  • Median Preferred Shares over the past 4 years was $3.6 billion (2016), compared with a mean of $3.6 billion.
  • Biggest five-year swings in Preferred Shares: grew 10.0% in 2016 and later changed 0.0% in 2017.
  • Teva Pharmaceutical Industries' Preferred Shares stood at $3.3 billion in 2015, then increased by 10.0% to $3.6 billion in 2016, then grew by 0.3% to $3.6 billion in 2017, then grew by 5.34% to $3.8 billion in 2018.
  • The last three reported values for Preferred Shares were $3.8 billion (Q3 2018), $3.8 billion (Q2 2018), and $3.7 billion (Q1 2018) per Business Quant data.